PPD skin test enhances bacillus Calmette-Guerin Tx in bladder CA

May 16, 2018

(HealthDay)—For patients with non-muscle invasive bladder cancer, undergoing the purified protein derivative skin test prior to bacillus Calmette-Guérin therapy may have therapeutic impact, according to a study published in the June issue of The Journal of Urology.

Naoya Niwa, M.D., from the Keio University School of Medicine in Tokyo, and colleagues treated 498 patients with non-muscle with adjuvant bacillus Calmette-Guérin; 320 of the patients underwent the purified derivative skin test one to two weeks before therapy.

The researchers found that the mean ± standard deviation five-year recurrence-free survival rate was 66.6 ± 2.8 percent and 59.1 ± 4.1 percent for patients who did and did not undergo the purified protein derivative skin test, respectively (P = 0.048). There were no significant differences between the groups in progression-free survival. Significant independent associations with tumor recurrence were seen for a history of recurrence, multiple tumors, the bacillus Calmette-Guérin Connaught strain, seven or more bacillus Calmette-Guérin instillations, and undergoing the purified protein derivative skin test. Overall, 24.1 and 15.2 percent of who did and did not undergo the test, respectively, had major bacillus Calmette-Guérin-related side effects (P = 0.02).

"Combination therapy with bacillus Calmette-Guérin using the purified protein derivative skin may improve the oncologic outcomes of that therapy," the authors write.

Explore further: Bacillus Calmette-Guerin vaccine may reduce atopic dermatitis

More information: Abstract/Full Text

Related Stories

Bacillus Calmette-Guerin vaccine may reduce atopic dermatitis

September 25, 2017
(HealthDay)—Bacillus Calmette-Guérin (BCG) vaccination within seven days of birth may reduce the risk of allergic diseases, including atopic dermatitis, according to a study published online Sept. 20 in Allergy.

Phase III research represents potential shift in standard of care for bladder cancer

April 2, 2012
Use of the Connaught strain of bacillus Calmette-Guérin, an adjuvant immunotherapy used in the treatment of non-muscle-invasive bladder cancer, significantly reduced cancer recurrence compared with the Tice strain of ...

Heating chemotherapy drugs may improve bladder cancer treatment

May 17, 2016
Scientists have found that heating the chemotherapy drug mitomycin-C prior to using it for treating bladder cancer may radically improve its efficacy. The findings, published in the International Journal of Hyperthermia, ...

Clinical trials of VPM1002 as a tuberculosis vaccine in newborns

March 24, 2015
The only tuberculosis vaccine currently approved, the Bacillus Calmette-Guérin (BCG) vaccine, protects children from the most severe forms of the disease in most cases but does not provide protection against the most common ...

Clinical trial could lead to new bladder cancer drug

November 24, 2015
A bladder cancer drug tested in a University of Hawai'i Cancer Center clinical trial is getting closer to Food and Drug Administration (FDA) approval. The new drug, an interleukin 15 superagonist complex (ALT-803), combined ...

Recommended for you

From the ashes of a failed pain drug, a new therapeutic path emerges

November 16, 2018
In 2013, renowned Boston Children's Hospital pain researcher Clifford Woolf, MB, BCh, Ph.D., and chemist Kai Johnsson, Ph.D., his fellow co-founder at Quartet Medicine, believed they held the key to non-narcotic pain relief. ...

Repurposing FDA-approved drugs can help fight back breast cancer

November 16, 2018
Screening Food and Drug Administration (FDA)-approved compounds for their ability to stop cancer growth in the lab led to the finding that the drug flunarizine can slow down the growth of triple-negative breast cancer in ...

Traditional chemotherapy superior to new alternative for oropharyngeal cancers

November 16, 2018
A drug increasingly used in combination with radiotherapy to treat a type of cancer that forms in the tonsils or the base of the tongue is inferior to a previously favored option, according to a large, clinical trial led ...

Standard chemotherapy treatment for HPV-positive throat cancer remains the most effective, study finds

November 15, 2018
A new study funded by Cancer Research UK and led by the University of Birmingham has found that the standard chemotherapy used to treat a specific type of throat cancer remains the most effective.

New 'SLICE' tool can massively expand immune system's cancer-fighting repertoire

November 15, 2018
Immunotherapy can cure some cancers that until fairly recently were considered fatal. In addition to developing drugs that boost the immune system's cancer-fighting abilities, scientists are becoming expert at manipulating ...

Anti-malaria drugs have shown promise in treating cancer, and now researchers know why

November 15, 2018
Anti-malaria drugs known as chloroquines have been repurposed to treat cancer for decades, but until now no one knew exactly what the chloroquines were targeting when they attack a tumor. Now, researchers from the Abramson ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.